- Home
- BTM vs CGTX Comparison
BTM vs CGTX Comparison
Compare BTM & CGTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BTM
- CGTX
- Stock Information
- Founded
- BTM 2016
- CGTX 2007
- Country
- BTM United States
- CGTX United States
- Employees
- BTM N/A
- CGTX N/A
- Industry
- BTM Finance: Consumer Services
- CGTX Biotechnology: Pharmaceutical Preparations
- Sector
- BTM Finance
- CGTX Health Care
- Exchange
- BTM Nasdaq
- CGTX Nasdaq
- Market Cap
- BTM 23.1M
- CGTX 23.1M
- IPO Year
- BTM N/A
- CGTX 2021
- Fundamental
- Price
- BTM $1.69
- CGTX $0.30
- Analyst Decision
- BTM Strong Buy
- CGTX Strong Buy
- Analyst Count
- BTM 2
- CGTX 5
- Target Price
- BTM $4.35
- CGTX $6.13
- AVG Volume (30 Days)
- BTM 138.9K
- CGTX 803.7K
- Earning Date
- BTM 05-15-2025
- CGTX 05-07-2025
- Dividend Yield
- BTM N/A
- CGTX N/A
- EPS Growth
- BTM N/A
- CGTX N/A
- EPS
- BTM N/A
- CGTX N/A
- Revenue
- BTM $573,703,000.00
- CGTX N/A
- Revenue This Year
- BTM $7.48
- CGTX N/A
- Revenue Next Year
- BTM $0.05
- CGTX N/A
- P/E Ratio
- BTM N/A
- CGTX N/A
- Revenue Growth
- BTM N/A
- CGTX N/A
- 52 Week Low
- BTM $0.93
- CGTX $0.31
- 52 Week High
- BTM $3.52
- CGTX $2.95
- Technical
- Relative Strength Index (RSI)
- BTM 65.49
- CGTX 31.49
- Support Level
- BTM $1.36
- CGTX $0.40
- Resistance Level
- BTM $1.58
- CGTX $0.47
- Average True Range (ATR)
- BTM 0.12
- CGTX 0.04
- MACD
- BTM 0.01
- CGTX -0.01
- Stochastic Oscillator
- BTM 87.50
- CGTX 11.16
About BTM Bitcoin Depot Inc.
Bitcoin Depot Inc owns and operates the largest network of BTMs across North America where customers can buy and sell Bitcoin. Bitcoin Depot helps power the digital economy for users of cash. It has locations across the U.S. and Canada at, among others, the following types of retailers: Convenience Stores and Gas Station Chains, Pharmacies and Grocers and Mall Operators.
About CGTX Cognition Therapeutics Inc.
Cognition Therapeutics Inc is a clinical-stage biopharmaceutical company engaged in the discovery and development of, small-molecule therapeutics targeting age-related degenerative diseases and disorders of the central nervous system and retina. Its product candidate CT1812, is an orally delivered, small-molecule antagonist designed to penetrate the blood-brain barrier and bind selectively to the S2R complex.